Treatment for glioblastoma (GBM)
Intended for US audiences only.
Optune® Novocure™

Quick facts about Optune®

Optune is a device

Optune is a noninvasive, portable device that is classified as durable medical equipment (DME). The complete system includes an electric field generator, a connection cable and box, 4 transducer arrays, 4 batteries along with a charger, power supply, and carrying bag.

Electric field generator, a connection cable and box, 4 transducer arrays, 4 batteries along with a charger, power supply, and carrying bag

How Optune works

Optune delivers Tumor Treating Fields (TTFields) to selectively disrupt mitosis in dividing cancer cells.1 To learn more, visit Optune MOA.

How patients use Optune

Optune is comprised of an electric field generator, a connection cable and box, 4 transducer arrays, and 3 batteries along with a charger, power supply, and carrying bag.

  • Transducer arrays are applied to the shaved scalp and must be changed at least 2 times per week (every 4 days at most)

  • Portable for use in normal daily activities

    • Except for activities that may result in the device or transducer arrays becoming wet. Getting the device wet may cause it damage, and getting the transducer arrays very wet is likely to cause the transducer arrays to come loose from the head

  • Optune should be worn ≥18 hours per day1

    • Compliance was a predictor of improved overall survival on Optune in the EF-11 trial1

To date, over 5000 patients have been treated with Optune2,*

*Commercial and clinical trials patients.

How to start patients on Optune
  1. Prescribe: Certified physician prescribes Optune
    Note: New prescription patients will be trained and started on the second generation Optune System.

  2. Submit: Novocure will confirm receipt of all submitted documents within 24 hours

  3. Shipping: Once the prescription is processed and coverage is verified, Novocure ships the Optune Treatment Kit to your patient’s designated Device Support Specialist (DSS)

  4. Initiate: DSS delivers the Optune Treatment Kit to your patient and completes technical training in the home (or clinic)

Optune can only be prescribed by certified physicians. Certification training can be provided to you by Novocure, or you can refer your patient to a certified physician.

Optune is available at more than 250 centers across the United States. To find out if there is a center near you, visit the Certified Treatment Centers page.

References: 1. Optune Instructions For Use. Novocure 2016. 2. Novocure Data on File. OPT-116.2.

A growing network

Search the treatment centers prescribing Optune.

View map

nCompass™ support program

Find out more about access and reimbursement assistance, 24/7 technical support, and starting patients on Optune.

Learn more

OPT-055.4-10


Indications For Use

Optune is intended as a treatment for adult patients (22 years of age or older) with histologically-confirmed glioblastoma multiforme (GBM).

Optune with temozolomide is indicated for the treatment of adult patients with newly diagnosed, supratentorial glioblastoma following maximal debulking surgery, and completion of radiation therapy together with concomitant standard of care chemotherapy.

For the treatment of recurrent GBM, Optune is indicated following histologically-or radiologically-confirmed recurrence in the supratentorial region of the brain after receiving chemotherapy. The device is intended to be used as a monotherapy, and is intended as an alternative to standard medical therapy for GBM after surgical and radiation options have been exhausted.

Important Safety Information

Contraindications

Do not use Optune in patients with an active implanted medical device, a skull defect (such as, missing bone with no replacement), or bullet fragments. Use of Optune together with implanted electronic devices has not been tested and may theoretically lead to malfunctioning of the implanted device. Use of Optune together with skull defects or bullet fragments has not been tested and may possibly lead to tissue damage or render Optune ineffective.

Do not use Optune in patients that are known to be sensitive to conductive hydrogels. In this case, skin contact with the gel used with Optune may commonly cause increased redness and itching, and rarely may even lead to severe allergic reactions such as shock and respiratory failure.

Warnings and Precautions

Optune can only be prescribed by a healthcare provider that has completed the required certification training provided by Novocure (the device manufacturer).

Do not prescribe Optune for patients that are pregnant, you think might be pregnant or are trying to get pregnant, as the safety and effectiveness of Optune in these populations have not been established.

The most common (≥10%) adverse events involving Optune in combination with temozolomide were thrombocytopenia, nausea, constipation, vomiting, fatigue, medical device site reaction, headache, convulsions, and depression.

The most common (≥10%) adverse events seen with Optune monotherapy were medical device site reaction and headache.

The following adverse reactions were considered related to Optune when used as monotherapy: medical device site reaction, headache, malaise, muscle twitching, fall and skin ulcer.

Use of Optune in patients with an inactive implanted medical device in the brain has not been studied for safety and effectiveness, and use of Optune in these patients could lead to tissue damage or lower the chance of Optune being effective.

If the patient has an underlying serious skin condition on the scalp, evaluate whether this may prevent or temporarily interfere with Optune treatment.


Please click here to see the Optune Instructions For Use (IFU) for complete information regarding the device's indications, contraindications, warnings, and precautions.

Patient Journey videos on this site depict actual patients and caregivers. All other depictions of patients, caregivers and health care professionals are actor portrayals.

Indications For Use

Optune is intended as a treatment for adult patients (22 years of age or older) with histologically-confirmed glioblastoma multiforme (GBM).